The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
Open accessAbstract
Purpose: Perivascular epithelioid cell tumors (PEComas) represent a family of mesenchymal neoplasms, mechanistically linked through activation of the mTOR signaling pathway. There is no known effective therapy for PEComa, and the molecular pathophysiology of aberrant mTOR signaling provided us with a scientific rationale to target this pathway therapeutically. On this mechanistic basis, we treated three consecutive patients with metastatic PEComa with an oral mTOR inhibitor, sirolimus. Patients and Methods: Patients with advanced PEComa were treated with sirolimus and consented to retrospective collection of data from their medical records and analysis of archival tumor specimens. Tumor response was determined by computed tomography scans obtained at the clinical discretion of the treating physicians. Tumors were assessed for immunohistochemical evidence of mTORC1 activation and genetic evidence of alterations in TSC1 and TSC2. Results: Radiographic responses to sirolimus were observed in all patients. PEComas demonstrated loss of TSC2 protein expression and evidence of baseline mTORC1 activation. Homozygous loss of TSC1 was identified in one PEComa. Conclusion: Inhibition of mTORC1, pathologically activated by loss of the TSC1/TSC2 tumor suppressor complex, is a rational mechanistic target for therapy in PEComas. The clinical activity of sirolimus in PEComa additionally strengthens the pathobiologic similarities linking PEComas to other neoplasms related to the tuberous sclerosis complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
Self-citationPEComa: what do we know so far?
Hornick, J. L., & Fletcher, C. D. �. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02316.x · Cited by 500
Self-citationPerivascular epithelioid cell neoplasms: pathology and pathogenesis
Folpe, A. L., & Kwiatkowski, D. J. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.05.011 · Cited by 401
Self-citationBenvenuto, G., Li, S., Brown, S. J., Braverman, R., Vass, W. C., Cheadle, J. P., Halley, D. J., Sampson, J. R., Wienecke, R., & DeClue, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1204009 · Cited by 252
Kenerson, H., Folpe, A. L., Takayama, T. K., & Yeung, R. S. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.01.028 · Cited by 250
Pan, C., Chung, M., Ng, K., Liu, C., Wang, J., Chai, C., Huang, S., Chen, P., & Ho, D. (2008) · The Journal of Pathology · doi:10.1002/path.2289 · Cited by 221
Kozlowski, P., Roberts, P., Dabora, S., Franz, D., Bissler, J., Northrup, H., Au, K. S., Lazarus, R., Domanska-Pakiela, D., Kotulska, K., et al. (2007) · Human Genetics · doi:10.1007/s00439-006-0308-9 · Cited by 182
Self-citationPhospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy
Iwenofu, O. H., Lackman, R. D., Staddon, A. P., Goodwin, D. G., Haupt, H. M., & Brooks, J. S. (2007) · Modern Pathology · doi:10.1038/modpathol.3800995 · Cited by 137
Hofbauer, G. F. L., Marcollo-Pini, A., Corsenca, A., Kistler, A. D., French, L. E., Wthrich, R. P., & Serra, A. L. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08677.x · Cited by 135
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Metadata
- Authors
- Wagner, A. J., Malinowska-Kolodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. M., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., Kwiatkowski, D. J., & Maki, R. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-10
- Volume
- 28
- Issue
- 5
- Pages
- 835-840
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109038438
- Cited by
- 399
- References
- 14
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. https://app.cochat.ai/papers/10.1200/jco.2009.25.2981
- The paper
- Wagner, A. J., Malinowska-Kolodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. M., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., Kwiatkowski, D. J., & Maki, R. G. (2010). Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.25.2981
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.